Novel modalities of recently approved drugs
Dr Sheraz Gul reviews the drug approvals from 2021 and highlights the novel modalities of molecules that target KRAS and HIF-2α, which have historically been considered as undruggable.
List view / Grid view
Articles
Uniting industry and academia for phenotypic drug discovery
A collaboration between Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) has been established to source cellular functional assays from the global academic community, with the goal of developing novel screens and identifying targets and therapeutic candidates for unmet medical needs. Here, Dr Denise Barrault, Director of…
Driving precision neurology forwards with iPSCs and new assays
Precision medicine in neurology is limited by a dearth of clinically relevant models. However, here Dr Evangelos Kiskinis, Assistant Professor at Northwestern University Feinberg School of Medicine, discusses how new technologies such as bioelectronic assays enable real-time, long-term analysis of neurological diseases in a dish, offering a pathway towards identifying…
Drug Target Review Assays ebook 2022
In this ebook, you can find articles on the development of novel assays and technology - download now for free!
Drug Target Review Vaccine Development ebook 2022
In this ebook, find articles on vaccination strategies for neurodegenerative diseases and the benefits of mRNA vaccine platforms against latent viruses.
Enhancing confocal microscopy with AI
Improving processes in the lab can enable researchers to spend their time on other tasks and increase the accuracy of their findings, including when imaging. In this Q&A, Dr Hari Shroff from the US National Institutes of Health (NIH) discusses his recent study, published in Nature where confocal microscopy was…
An equal seat at the table for AI in pharmaceutical discovery
This article explores the current state of artificial intelligence (AI) in drug discovery and development, discussing the obstacles holding back wider adoption. Dr Mark Eller, Senior Vice President of Research and Development at Aria Pharmaceuticals, makes the case that to succeed, AI must be integrated as a partner alongside core…
Drug Target Review – Issue 1 2022
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
The case for improving absorption for cannabinoids using ethosomes
Michael Sassano and Anthony DeMeo from Somai Pharmaceuticals discuss using ethosomes as an improved method to deliver cannabinoids to the human body.
Innovative treatments: the new frontier for mental health
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
Pre-clinical models of endometriosis and their value for translational research
In this exclusive Q&A, Dr Paulina Nunez-Badinez, Scientific Researcher at Bayer AG, discusses pre-clinical research of pain related to endometriosis and why there is a lack of research around this area.
CRISPR activation screening: finding genes that interact with SARS-CoV-2
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
Transformational machine learning approach could accelerate drug design
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
CRISPR screens and novel drug targets
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
Treating cancer patients with cancer anorexia-cachexia syndrome
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
